Source: Inside Precision Medicine, by Malorye Branca. AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- FDA approved Guardant360 CDx for serial testing with camizestrant in HR-positive, HER2-negative advanced or metastatic breast cancer.
- The test is used every three months to detect emerging ESR1 mutations before clinical or radiographic progression.
- The source provides no study enrollment, detailed outcome data, safety data, or evidence for other breast-cancer subtypes.
The U.S. Food and Drug Administration has approved Guardant Health's Guardant360 CDx blood test for repeated use in a defined group of people with advanced breast cancer, alongside AstraZeneca's ETCAMAH, or camizestrant. The approval makes the test the first FDA-approved liquid-biopsy companion diagnostic for serial testing in breast cancer, according to Guardant Health. Rather than waiting for an imaging scan to show that a tumor has grown, clinicians can use the test every three months to look for an emerging ESR1 mutation, a genetic change linked to treatment resistance. The intended patients have hormone receptor-positive, HER2-negative advanced or metastatic breast cancer and are receiving therapy that includes a CDK4/6 inhibitor. In the SERENA-6 treatment approach described by the company, using Guardant360 CDx to guide a switch to camizestrant plus a CDK4/6 inhibitor reduced the risk of disease progression or death by more than 50%. The central idea is to detect molecular evidence that a cancer may be escaping treatment before that change becomes apparent through symptoms or radiographic imaging. The decision does not mean that every blood-test result independently proves a tumor has progressed, but it establishes a regulated route for using serial molecular monitoring to inform a specific treatment decision. It also reflects a multiyear collaboration between Guardant Health and AstraZeneca aimed at bringing Guardant's testing technology into clinical development.
Testing for Resistance Before a Scan Changes
Traditional cancer monitoring often relies heavily on scans. A scan can reveal whether measurable tumors have enlarged, shrunk, or remained stable, but it generally captures a physical change that may occur after cancer cells have already begun adapting to therapy.
Guardant360 CDx uses a liquid biopsy, meaning it analyzes tumor-derived genetic material found in a blood sample. Think of it as looking for fragments of a changing instruction manual that cancer cells shed into the bloodstream, rather than waiting to see whether the full tumor has become visibly larger on an image.
What Serial Use Means
In this setting, serial or longitudinal testing means repeating the same molecular test over time, not ordering it once at diagnosis. The newly approved use calls for testing every three months during therapy for eligible patients.
The purpose is to identify emerging ESR1 mutations before clinical progression or radiographic progression. Clinical progression refers to worsening signs or symptoms of disease, while radiographic progression means changes detected on imaging such as computed tomography or magnetic resonance imaging scans.
The Patients Covered by the Approval
The companion-diagnostic approval applies to people with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Hormone receptor-positive tumors use signals from hormones such as estrogen to support their growth, while HER2-negative indicates the cancer does not have high levels of the HER2 growth-promoting protein.
These labels matter because breast cancer is not one disease. A treatment and testing strategy designed for this biological subtype cannot automatically be assumed to apply to HER2-positive disease, triple-negative breast cancer, early-stage disease, or every patient with metastatic cancer.
Why ESR1 Is the Target
ESR1 is the gene that provides instructions for the estrogen receptor, a protein central to many hormone receptor-positive breast cancers. When ESR1 mutations emerge, they can change how a tumor responds to endocrine therapies, treatments that work by blocking or altering hormone signaling.
Guardant Health's stated rationale is that detecting this mutation can signal that the cancer is beginning to escape its current treatment. That may give clinicians an opportunity to alter therapy before conventional imaging shows measurable progression, though the test is specifically approved as a companion diagnostic within the camizestrant treatment approach described by the company.
Connecting the Test to Camizestrant
A companion diagnostic is a test used to identify patients who may benefit from, or should receive, a particular medicine. Here, Guardant360 CDx is paired with AstraZeneca's ETCAMAH, also called camizestrant, for patients who meet the approval's disease and treatment criteria.
According to Guardant Health, Guardant360 CDx-guided treatment with camizestrant plus a CDK4/6 inhibitor reduced the risk of disease progression or death by more than 50%. CDK4/6 inhibitors are drugs that block proteins cancer cells can use to move through the cell-division cycle, acting somewhat like a brake on cell multiplication.
The SERENA-6 Approach
The company describes this treatment-monitoring model as the SERENA-6 paradigm. Its distinguishing feature is the timing of the intervention: a therapy decision is guided by a molecular sign of resistance found in blood, rather than being triggered only after visible disease progression.
That is a meaningful distinction, but it should not be confused with a general declaration that scans are no longer needed. The source describes an approved use for a particular blood test, mutation, cancer subtype, and therapy combination, not a replacement for all established forms of clinical and imaging follow-up.
Why This Matters
The approval moves liquid biopsy beyond a one-time snapshot of tumor genetics and toward repeated monitoring during treatment. For patients and clinicians, the potential value is practical: a routine blood draw may reveal a therapy-resistance signal earlier than a scan can show tumor growth.
It also gives drug developers and diagnostic companies a concrete example of how molecular monitoring can be built into treatment strategy. Guardant Health's multiyear collaboration with AstraZeneca focused on integrating Guardant products and capabilities into clinical development, and this approval is the reported outcome for Guardant360 CDx in breast cancer.
What Comes Next
The announcement does not provide study enrollment, detailed outcome data, safety information, or evidence that the approach works across other breast-cancer subtypes or treatment regimens. Future evidence will determine how broadly serial liquid-biopsy monitoring can be applied, but this FDA action establishes an early regulated model for acting on emerging ESR1 mutations before conventional progression is observed.